Based on current data and ELN 2017 and 2022 recommendations, FLT3 mutation test results for all newly diagnosed and R/R AML patients should be available in electronic patient records within 2–5 calendar days. It should be noted that this timeline may become more acute, as FLT3 inhibitors may in the future be used earlier in upfront AML therapy. This evidence concerns the gene FLT3 and acute myeloid leukemia.